{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:42:34Z","timestamp":1790649754954,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Hereditary hemorrhagic telangiectasia is an autosomal dominant condition with an estimated prevalence of 1 in 5000. It is characterized by the presence of abnormalities of vascular structures, and may affect many organ systems, including the lungs, brain, spinal cord, gastrointestinal tract, and liver. A causative mutation is identified in approximately 97% of patients with definite hereditary hemorrhagic telangiectasia in one of three genes including a mutation in endoglin, a mutation in a locus mapped to chromosome 5, and an activin receptor-like kinase-1 (<jats:italic>ACVRL1<\/jats:italic>) mutation that is associated with an increased incidence of primary pulmonary hypertension. Pulmonary arterial hypertension is a rare (15\u201325 cases per million people) but severe vascular disorder. Heritable pulmonary arterial hypertension is associated with several gene mutations, with 75% having a mutation in the bone morphogenetic protein receptor 2 (BMPR2). However, the remaining 25% of patients have other associated genetic mutations including <jats:italic>ACVLR1<\/jats:italic>, which is also associated with hereditary hemorrhagic telangiectasia. Pulmonary arterial hypertension is a rare complication in patients with hereditary hemorrhagic telangiectasia (&lt;\u00a01% of the hereditary hemorrhagic telangiectasia population). We describe a case report with this rare occurrence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 70-year-old white\/caucasian Irish male presented for screening for hereditary hemorrhagic telangiectasia due to a history of recurrent epistaxis (once\/week) and a family history suggestive of pulmonary hypertension. Genetic testing confirmed an <jats:italic>ACVRL1<\/jats:italic> mutation, while an echocardiogram and right heart catheterization confirmed pulmonary arterial hypertension. On examination, he had several mucocutaneous telangiectasia across his face. He was commenced on tadalafil and macitentan. However, this led to increased iron deficiency anemia and pedal edema. Selexipag was also added to his drug regime. He continues to require intermittent admissions for diuresis and blood transfusions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The association of hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension is rare (&lt;\u00a01%). Here we describe a case of hereditary hemorrhagic telangiectasia complicated with pulmonary arterial hypertension as a result of an <jats:italic>ACVRL1<\/jats:italic> mutation. We also describe the clinical challenges of treating these two conditions together, as treatment options for pulmonary arterial hypertension tend to worsen hereditary hemorrhagic telangiectasia symptoms.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-022-03296-9","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T14:02:38Z","timestamp":1646143358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pulmonary arterial hypertension in hereditary hemorrhagic telangiectasia associated with ACVRL1 mutation: a case report"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7813-7360","authenticated-orcid":false,"given":"L. J.","family":"Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. M.","family":"Kerins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. P.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. M.","family":"O Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"issue":"3","key":"3296_CR1","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.crad.2016.12.002","volume":"72","author":"DJ Ryan","year":"2017","unstructured":"Ryan DJ, O\u2019Connor TM, Murphy MM, Brady AP. Follow-up interval for small untreated pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia. Clin Radiol. 2017;72(3):236\u201341.","journal-title":"Clin Radiol"},{"issue":"2","key":"3296_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11845-008-0220-5","volume":"178","author":"AP Brady","year":"2009","unstructured":"Brady AP, Murphy MM, O\u2019Connor TM. Hereditary haemorrhagic telangiectasia: a cause of preventable morbidity and mortality. Ir J Med Sci. 2009;178(2):135\u201346.","journal-title":"Ir J Med Sci"},{"issue":"2","key":"3296_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/jmg.2009.069013","volume":"48","author":"ME Faughnan","year":"2011","unstructured":"Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, HHT Foundation International\u2014Guidelines Working Group, et\u00a0al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet. 2011;48(2):73\u201387.","journal-title":"J Med Genet"},{"issue":"14","key":"3296_CR4","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1056\/NEJM199510053331407","volume":"333","author":"AE Guttmacher","year":"1995","unstructured":"Guttmacher AE, Marchuk DA, White RI Jr. Hereditary haemorrhagic telangiectasia. N Engl J Med. 1995;333(14):918\u201324.","journal-title":"N Engl J Med"},{"key":"3296_CR5","doi-asserted-by":"publisher","first-page":"66e7","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","volume":"91","author":"CL Shovlin","year":"2000","unstructured":"Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, et\u00a0al. Diagnostic criteria for hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000;91:66e7.","journal-title":"Am J Med Genet"},{"key":"3296_CR6","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1136\/thx.54.8.714","volume":"54","author":"CL Shovlin","year":"1999","unstructured":"Shovlin CL, Letarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax. 1999;54:714\u201329.","journal-title":"Thorax"},{"key":"3296_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0033-8389(05)70172-X","volume":"38","author":"S Saluja","year":"2000","unstructured":"Saluja S, Henderson KJ, White RI. Embolotherapy in the bronchial and pulmonary circulations. Radiol Clin N Am. 2000;38:425\u201348.","journal-title":"Radiol Clin N Am"},{"key":"3296_CR8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1136\/jmg.2004.028712","volume":"42","author":"SG Cole","year":"2005","unstructured":"Cole SG, Begbie ME, Wallace GMF, Shovlin CL. A new locus for hereditary haemorrhagic telangiectasia HHT3 maps to chromosome 5. J Med Genet. 2005;42:577\u201382.","journal-title":"J Med Genet"},{"key":"3296_CR9","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S0140-6736(04)15732-2","volume":"363","author":"CJ Gallione","year":"2004","unstructured":"Gallione CJ, Repetto GM, Legius E, Rustgi AK, Schelley SL, Tejpar S, et\u00a0al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet. 2004;363:852\u20139.","journal-title":"Lancet"},{"key":"3296_CR10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1136\/jmg.2006.041517","volume":"43","author":"CJ Gallione","year":"2006","unstructured":"Gallione CJ, Richards JA, Letteboer TG, Rushlow D, Prigoda NL, Leedom TP, et\u00a0al. SMAD4 mutations found in unselected HHT patients. J Med Genet. 2006;43:793\u20137.","journal-title":"J Med Genet"},{"key":"3296_CR11","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.3390\/ijms19103203","volume":"19","author":"VMM Vorselaars","year":"2018","unstructured":"Vorselaars VMM, Hosman AE, Westermann CJJ, Snijder RJ, Mager JJ, Goumans MJ, Post MC. Pulmonary arterial hypertension and hereditary haemorrhagic telangiectasia. Int J Mol Sci. 2018;19:3203.","journal-title":"Int J Mol Sci"},{"key":"3296_CR12","doi-asserted-by":"publisher","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","volume":"53","author":"G Simonneau","year":"2019","unstructured":"Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et\u00a0al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53:1801913.","journal-title":"Eur Respir J"},{"key":"3296_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","volume":"115","author":"GE Alonzo","year":"1991","unstructured":"Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et\u00a0al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115:343\u20139.","journal-title":"Ann Intern Med"},{"key":"3296_CR14","doi-asserted-by":"publisher","first-page":"D13","DOI":"10.1016\/j.jacc.2013.10.035","volume":"62","author":"F Soubrier","year":"2013","unstructured":"Soubrier F, Chung WK, Machado R, Grunig E, Aldred M, Geraci M, et\u00a0al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62:D13\u201321.","journal-title":"J Am Coll Cardiol"},{"key":"3296_CR15","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1164\/rccm.201205-0886OC","volume":"186","author":"EK Larkin","year":"2012","unstructured":"Larkin EK, Newman JH, Austin ED, Hemnes AR, Wheeler L, Robbins IM, et\u00a0al. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;186:892\u20136.","journal-title":"Am J Respir Crit Care Med"},{"key":"3296_CR16","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/s41467-018-03672-4","volume":"9","author":"S Graf","year":"2018","unstructured":"Graf S, Haimel M, Bleda M, Hadinnapola C, Southgate L, Li W, et\u00a0al. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nat Commun. 2018;9:1416.","journal-title":"Nat Commun"},{"key":"3296_CR17","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3389\/fgene.2014.00456","volume":"5","author":"E Tillet","year":"2015","unstructured":"Tillet E, Bailly S. Emerging roles of BMP9 and BMP10 in hereditary haemorrhagic telangiectasia. Front Genet. 2015;5:456.","journal-title":"Front Genet"},{"key":"3296_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12890-016-0183-7","volume":"16","author":"G Wang","year":"2016","unstructured":"Wang G, Fan R, Ji R, Zou W, Penny DJ, Varghese NP, Fan Y. Novel homozygous BMP9 nonsense mutation causes pulmonary arterial hypertension: a case report. BMC Pulm Med. 2016;16:17.","journal-title":"BMC Pulm Med"},{"issue":"2","key":"3296_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045894018759918","volume":"8","author":"W Li","year":"2018","unstructured":"Li W, Xiong C-M, Gu Q, Wang X-T, Cheng XI, Huang L, et\u00a0al. The clinical characteristics and long-term prognosis of pulmonary arterial hypertension associated with hereditary haemorrhagic telangiectasia. Pulm Circ. 2018;8(2):1\u201311.","journal-title":"Pulm Circ"},{"issue":"1","key":"3296_CR20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13023-017-0632-2","volume":"12","author":"MM Serra","year":"2017","unstructured":"Serra MM, Besada CH, Cabana Cal A, Saenz A, Stefani CV, Bauso D, et\u00a0al. Central nervous system manganese induced lesions and clinical consequences in patients with hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis. 2017;12(1):92.","journal-title":"Orphanet J Rare Dis"},{"key":"3296_CR21","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1183\/09031936.00061308","volume":"33","author":"ME Faughnan","year":"2009","unstructured":"Faughnan ME, Granton JT, Young LH. The pulmonary vascular complications of hereditary haemorrhagic telangiectasia. Eur Respir J. 2009;33:1186\u201394.","journal-title":"Eur Respir J"},{"key":"3296_CR22","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1164\/rccm.200908-1284OC","volume":"181","author":"B Girerd","year":"2010","unstructured":"Girerd B, Montani D, Coulet F, Sztrymf B, Yaici A, Jais X, et\u00a0al. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med. 2010;181:851\u201361.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"3296_CR23","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick RN, Delcroix M, Gali\u00e8 N, Ghofrani HA, SERAPHIN Investigators, et\u00a0al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809\u201318.","journal-title":"N Engl J Med"},{"key":"3296_CR24","doi-asserted-by":"publisher","first-page":"2000673","DOI":"10.1183\/13993003.00673-2020","volume":"56","author":"O Sitbon","year":"2020","unstructured":"Sitbon O, Cottin V, Canuet M, Clerson P, Gressin V, Perchenet L, et\u00a0al. Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. Eur Respir J. 2020;56:2000673.","journal-title":"Eur Respir J"},{"key":"3296_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40256-017-0260-1","volume":"18","author":"P Jansa","year":"2018","unstructured":"Jansa P, Pulido T. Macitentan in pulmonary arterial hypertension: a focus on combination therapy in the SERAPHIN trial. Am J Cardiovasc Drugs. 2018;18:1\u201311.","journal-title":"Am J Cardiovasc Drugs"},{"key":"3296_CR26","first-page":"A2299","volume":"195","author":"KM Chin","year":"2017","unstructured":"Chin KM, Channick R, Kim NH, Muros-Le Rouzic E, Selej M, McLaughlin V. OPUS registry: treatment patterns with macitentan in patients with pulmonary arterial hypertension. Am J Crit Care Med. 2017;195:A2299.","journal-title":"Am J Crit Care Med"},{"issue":"9","key":"3296_CR27","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1517\/14712598.2013.813478","volume":"13","author":"T Kanellopoulou","year":"2013","unstructured":"Kanellopoulou T, Alexopoulou A. Bevacizumab in the treatment of hereditary haemorrhagic telangiectasia. Expert Opin Biol Ther. 2013;13(9):1315\u201323.","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"3296_CR28","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/MCG.0b013e3182688d49","volume":"47","author":"A Lupu","year":"2013","unstructured":"Lupu A, Stefanescu C, Treton X, Attar A, Corcos O, Bouhnik Y. Bevacizumab as rescue treatment for severe recurrent gastrointestinal bleeding in hereditary haemorrhagic telangiectasia. J Clin Gastroenterol. 2013;47(3):256\u20137.","journal-title":"J Clin Gastroenterol"},{"issue":"9","key":"3296_CR29","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1001\/jama.2012.250","volume":"307","author":"S Dupuis-Girod","year":"2012","unstructured":"Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, et\u00a0al. Bevacizumab in patients with hereditary haemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA. 2012;307(9):948\u201355.","journal-title":"JAMA"},{"issue":"13","key":"3296_CR30","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.12998\/wjcc.v9.i13.3079","volume":"9","author":"J Wu","year":"2021","unstructured":"Wu J, Yuan Y, Wang X, Shao DY, Liu LG, He J, Li P. Pulmonary arterial hypertension in a patient with hereditary haemorrhagic telangiectasia and family gene analysis: a case report. World J Clin Cases. 2021;9(13):3079\u201389.","journal-title":"World J Clin Cases"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03296-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-022-03296-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03296-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T15:03:39Z","timestamp":1646147019000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-022-03296-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3296"],"URL":"https:\/\/doi.org\/10.1186\/s13256-022-03296-9","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]},"assertion":[{"value":"6 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There are no competing interests for any of the contributing authors","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}